NANOG and non-small cell lung carcinoma: This finding was the same as that in Teng and Wang’s report, namely that Nanog and Oct-4 levels were significantly elevated in drug-resistant lung cancer cells [63,64] and in Wang and Zhang’s report, which showed that CDH2 contributes to acquired drug resistance in NSCLC [65,66].